What kind of medicine is being discussed?
Get the exact name. Then ask which set of rules applies.
Peptide is a description, not a treatment plan
A peptide is a substance made of a short chain of tiny parts joined together; insulin is one example.
Think of the links in a short chain. The word describes how the substance is put together, rather than what it would do for you.
The label peptide says nothing about a product’s permission for use as medicine as of September 2026.
Ask for the name of the actual medicine, rather than accepting peptide therapy as the whole explanation.
Ask whether it is an approved product
The semaglutide brands Ozempic and Wegovy, alongside the tirzepatide brands Mounjaro and Zepbound, have products approved by the FDA for particular health problems, including diabetes and weight management, as of September 2026.
Ozempic and Mounjaro are used for type 2 diabetes; Wegovy and Zepbound are used for weight management.
FDA means the US Food and Drug Administration. Ask which product, which form, and which condition the proposed treatment is for. A conversation about longevity still needs those details.
Ask whether it is made to order
Compounding is preparing a medicine to order through a pharmacist, physician, or registered facility.
A compounded medicine receives neither FDA approval nor the agency’s review before sale, as of September 2026.
Have the clinician explain why the need under discussion could not be met by an approved product.
A bottle saying for research use only is not a care plan
As of September 2026, FDA warning letters describe sellers promoting products for human treatment while labelling them not for human consumption or for research use only.
In those letters, the FDA treated the products as unapproved medicines despite the wording on the labels.
Those words describe a product offered for laboratory work. They do not give you instructions for treatment. If a bottle has that label, ask a licensed clinician about a medicine intended for patient care.
The letters state the FDA’s concerns about named sellers. A court has not settled those concerns just because a letter was sent.